Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Bought by Woodline Partners LP

Woodline Partners LP lifted its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 110.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,410,520 shares of the company's stock after acquiring an additional 739,713 shares during the period. Woodline Partners LP owned 2.61% of Fulcrum Therapeutics worth $6,629,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in Fulcrum Therapeutics in the fourth quarter valued at approximately $38,000. Mariner LLC purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at about $78,000. Cantor Fitzgerald L. P. acquired a new position in Fulcrum Therapeutics during the fourth quarter worth approximately $94,000. Zacks Investment Management purchased a new stake in Fulcrum Therapeutics in the fourth quarter valued at approximately $99,000. Finally, Intech Investment Management LLC lifted its stake in Fulcrum Therapeutics by 74.9% in the fourth quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after buying an additional 13,057 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on FULC shares. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a research report on Thursday, May 15th. HC Wainwright reaffirmed a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $4.00 to $12.00 in a research note on Friday, May 23rd. Finally, Leerink Partnrs upgraded Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Fulcrum Therapeutics has an average rating of "Hold" and an average target price of $5.83.

Fulcrum Therapeutics Price Performance

Shares of FULC stock traded up $0.55 during mid-day trading on Wednesday, hitting $6.90. The stock had a trading volume of 997,779 shares, compared to its average volume of 970,585. The firm has a market cap of $372.46 million, a PE ratio of -22.26 and a beta of 2.29. The company's 50-day simple moving average is $4.16 and its 200-day simple moving average is $3.95. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. On average, analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.